DK1254663T3 - Antivirusmiddel - Google Patents

Antivirusmiddel

Info

Publication number
DK1254663T3
DK1254663T3 DK01110873T DK01110873T DK1254663T3 DK 1254663 T3 DK1254663 T3 DK 1254663T3 DK 01110873 T DK01110873 T DK 01110873T DK 01110873 T DK01110873 T DK 01110873T DK 1254663 T3 DK1254663 T3 DK 1254663T3
Authority
DK
Denmark
Prior art keywords
present
virus agent
virus
construct
gene encoding
Prior art date
Application number
DK01110873T
Other languages
English (en)
Inventor
Marina N Papuashvili
Original Assignee
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Ltd filed Critical Technologie Integrale Ltd
Application granted granted Critical
Publication of DK1254663T3 publication Critical patent/DK1254663T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01110873T 2001-05-04 2001-05-04 Antivirusmiddel DK1254663T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01110873A EP1254663B1 (en) 2001-05-04 2001-05-04 Anti-virus agent
US09/848,269 US20030176372A1 (en) 2001-05-04 2001-05-04 Anti-virus agent

Publications (1)

Publication Number Publication Date
DK1254663T3 true DK1254663T3 (da) 2005-03-21

Family

ID=46679311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01110873T DK1254663T3 (da) 2001-05-04 2001-05-04 Antivirusmiddel

Country Status (15)

Country Link
US (1) US20030176372A1 (da)
EP (1) EP1254663B1 (da)
JP (1) JP2005510455A (da)
CN (1) CN1527716A (da)
AT (1) ATE281838T1 (da)
CA (1) CA2446204A1 (da)
CZ (1) CZ20033288A3 (da)
DE (1) DE60107052T2 (da)
DK (1) DK1254663T3 (da)
ES (1) ES2234730T3 (da)
HU (1) HUP0400987A3 (da)
IL (1) IL158739A0 (da)
PL (1) PL367451A1 (da)
PT (1) PT1254663E (da)
WO (1) WO2002089817A2 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663397B (zh) * 2007-04-20 2015-04-22 宝生物工程株式会社 用于基因治疗的载体
JP6915870B2 (ja) * 2016-01-27 2021-08-04 国立大学法人北海道大学 ウイルスフリー植物体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973507A (en) * 1989-01-23 1990-11-27 Horian Richard C Thin wood laminate panel and method of fabrication
EP0479180A3 (en) * 1990-10-05 1992-08-26 Hoechst Aktiengesellschaft Virus resistant plants, method for their production

Also Published As

Publication number Publication date
CN1527716A (zh) 2004-09-08
US20030176372A1 (en) 2003-09-18
DE60107052D1 (de) 2004-12-16
IL158739A0 (en) 2004-05-12
PT1254663E (pt) 2005-04-29
EP1254663B1 (en) 2004-11-10
HUP0400987A2 (hu) 2004-08-30
ES2234730T3 (es) 2005-07-01
CA2446204A1 (en) 2002-11-14
WO2002089817A2 (en) 2002-11-14
DE60107052T2 (de) 2005-11-24
PL367451A1 (en) 2005-02-21
ATE281838T1 (de) 2004-11-15
EP1254663A1 (en) 2002-11-06
WO2002089817A3 (en) 2003-01-30
HUP0400987A3 (en) 2004-10-28
JP2005510455A (ja) 2005-04-21
CZ20033288A3 (cs) 2004-04-14

Similar Documents

Publication Publication Date Title
FR21C1037I1 (fr) Clades de virus adéno associés (aav), séquences, vecteurs les contenant et leurs utilisations
EA200701450A1 (ru) РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ATE550025T1 (de) Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna)
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
DE602004030583D1 (de) Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
WO2004028471A3 (en) Influenza therapeutic
DE69837708D1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
MXPA01010392A (es) Produccion de vacunas de virus con arn de hebra negativa atenuados a partir de secuencias de nucleotidos clonadas.
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
ATE294866T1 (de) Zellen, die virus-resistent und von viren infizierbar sind
DK1254663T3 (da) Antivirusmiddel
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
JP2008503569A5 (da)
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
EA200301089A1 (ru) Противовирусный агент
BR9801992A (pt) Processos para a preparação de vìrus da doença de marek usando linhas celulares contìnuas de mamìfero.
BR9903877A (pt) Composicões e métodos para a proteção de animais contra doença associada a lentivìrus, assim como o vìrus da imunodeficiência felina
DE69533167D1 (de) Impfstoffe gegen den hepatitis b und c virus
CA2086577A1 (en) Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene
ATE368117T1 (de) Komplette gensequenz des esel-leukozyten- impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung